Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey; Piscataway, New Jersey, USA.
Department of Infection Prevention, Robert Wood Johnson University Hospital Somerset, Somerville, New Jersey, USA.
Clin Infect Dis. 2021 Jul 1;73(1):e62-e68. doi: 10.1093/cid/ciaa545.
Studies have had conflicting results regarding the influence of acid-suppression medications (ASMs) during hospitalization on the recurrence of Clostridioides difficile infection (CDI).
A systematic review and meta-analysis investigating the association between recurrent CDI and ASM use in inpatients was performed. Relevant literature was identified using Medline, Google Scholar, and Web of Science. All human studies were considered regardless of publication date. Case-control and cohort studies and clinical trials were included if they contained the necessary information to calculate appropriate statistics related to the objective of this study. Review articles, meta-analyses, and commentaries were excluded; however, their references were searched to identify any studies missed. The random-effects model was selected since significant heterogeneity in study design was identified. To evaluate the sensitivity of the analysis various subgroup analyses were performed.
Our search identified 9 studies involving 5668 patients of whom 1003 (17.7%) developed recurrent CDI. Patients on ASM were 64% more likely to develop recurrent CDI than patients not on ASM (OR, 1.64; 95% CI, 1.13-2.38; P = .009; I2 = 79.54%). Proton pump inhibitor (PPI) use was associated with an 84% increased risk of recurrent CDI versus no ASM (OR, 1.84; 95% CI, 1.18-2.85; P = .007; I2 = 83.4%).
ASM use during hospitalization was associated with a 64% increase in recurrent CDI. The association was greater with PPI use. Due to significant heterogeneity in the analyses, additional studies are essential to further elucidate iatrogenic effects of ASM. Unnecessary PPI use should be discontinued.
关于住院期间使用抑酸药物(ASM)对艰难梭菌感染(CDI)复发的影响,已有研究结果相互矛盾。
系统回顾和荟萃分析调查了住院患者中 CDI 复发与 ASM 使用之间的关联。使用 Medline、Google Scholar 和 Web of Science 确定相关文献。无论发表日期如何,均考虑所有人类研究。如果病例对照研究和队列研究以及临床试验包含与本研究目标相关的适当统计信息,则将其纳入。排除综述文章、荟萃分析和评论;但是,搜索了它们的参考文献,以确定是否遗漏了任何研究。由于研究设计存在显著异质性,因此选择了随机效应模型。为了评估分析的敏感性,进行了各种亚组分析。
我们的搜索确定了 9 项涉及 5668 名患者的研究,其中 1003 名(17.7%)发生了复发性 CDI。使用 ASM 的患者发生复发性 CDI 的可能性比未使用 ASM 的患者高 64%(OR,1.64;95%CI,1.13-2.38;P=0.009;I2=79.54%)。与未使用 ASM 相比,使用质子泵抑制剂(PPI)与复发性 CDI 的风险增加 84%相关(OR,1.84;95%CI,1.18-2.85;P=0.007;I2=83.4%)。
住院期间使用 ASM 与复发性 CDI 增加 64%相关。与 PPI 相关的使用关联性更大。由于分析中存在显著的异质性,需要进一步研究以进一步阐明 ASM 的医源性影响。应停止不必要的 PPI 使用。